At a glance
- Originator Novartis
- Class Antihypertensives; Heart failure therapies
- Mechanism of Action ACE inhibitors; Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure; Hypertension
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 06 Aug 1998 No-Development-Reported for Congestive heart failure in USA (Unknown route)
- 06 Aug 1998 No-Development-Reported for Hypertension in USA (Unknown route)